Cartalax

Evidence review

Evidence grade D

Evidence is primarily from animal and laboratory studies; human efficacy and an established dose are absent.

Reviewed Aug 10, 2026 3 linked authoritative sources

Cartalax is the synthetic tripeptide AED (Ala-Glu-Asp) marketed as a cartilage “bioregulator.” It has no FDA-approved product, indication, or dose.

What Cartalax is

Cartalax is the synthetic tripeptide AED (Ala-Glu-Asp) marketed as a cartilage “bioregulator.” It has no FDA-approved product, indication, or dose.

Cartilage claims come from cell studies

Recent work examined AED in cultured rat chondrocytes and stem-cell differentiation models.^[1]^[2] No controlled human trial establishes Cartalax for osteoarthritis, pain, cartilage regeneration, mobility, or aging. A change in cultured-cell proliferation does not show that cartilage regrows inside a loaded human joint.

Safety is not established

Human absorption, distribution, metabolism, dose-response, adverse events, interactions, pregnancy use, and long-term effects are undefined. Product purity and sterility add separate risks for material sold outside an approved supply chain.

Regulatory status

Cartalax is unapproved in the United States. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.^[3] Teloryx does not publish a Cartalax dose or preparation protocol.